Notice Information
Notice Title
NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema
Notice Description
National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
Lot Information
Lot 1 - C1 Esterase - Recombinant IV (acute treatment)
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 3 - C1 Esterase - Plasma derived IV (prophylaxis treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 6 - LanadelumabNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 7 - BerotralstatNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 4 - C1 Esterase - Plasma derived Subcut (prophylaxis treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 5 - IcatibantNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 1 - C1 Esterase - Recombinant IV (acute treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 3 - C1 Esterase - Plasma derived IV (prophylaxis treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 6 - LanadelumabNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 7 - BerotralstatNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 4 - C1 Esterase - Plasma derived Subcut (prophylaxis treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 5 - IcatibantNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-0314ad
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/019862-2022
- Current Stage
- Award
- All Stages
- Tender, Award
Procurement Classification
- Notice Type
- Tender Notice
- Procurement Type
- Framework
- Procurement Category
- Goods
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- Not specified
- Awardee Scale
- Large, SME
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33141510 - Blood products
33141520 - Plasma extracts
33600000 - Pharmaceutical products
Notice Value(s)
- Tender Value
- £198,666,666 £100M-£1B
- Lots Value
- £7 Under £100K
- Awards Value
- Not specified
- Contracts Value
- £1
Notice Dates
- Publication Date
- 21 Jul 20224 years ago
- Submission Deadline
- 16 Mar 2022Expired
- Future Notice Date
- Not specified
- Award Date
- 20 Jun 20224 years ago
- Contract Period
- 1 Jul 2022 - 31 Dec 2023 1-2 years
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Active, Cancelled
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS England
- Additional Buyers
The NHS Commissioning Board (operating under the name of NHS England)
- Contact Name
- Available with D3 Tenders Premium →
- Contact Email
- Available with D3 Tenders Premium →
- Contact Phone
- Available with D3 Tenders Premium →
Buyer Location
- Locality
- LEEDS
- Postcode
- LS2 7UE
- Postcode Area
- Leeds
- Country
- England
-
- Major Region (ITL 1)
- TLE Yorkshire and The Humber
- Basic Region (ITL 2)
- TLE4 West Yorkshire
- Small Region (ITL 3)
- TLE42 Leeds
- Delivery Location
- Not specified
-
- Local Authority
- Leeds
- Electoral Ward
- Little London & Woodhouse
- Westminster Constituency
- Leeds Central and Headingley
Further Information
Open Contracting Data Standard (OCDS)
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.